Revenue
2020
2021
2022
2023
2024
2025
Longeveron Inc. (LGVN)
Price$6.74Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | $2.4M | $709,000 | $940,000 | $708,000 | $55,000 |
| Gross profit | $803,000 | $1.9M | $221,000 | $497,000 | $590,000 | $1.8M |
| Gross margin | 66.97% | 78.76% | 31.17% | 52.87% | 83.33% | 3,320.00% |
| Research & development | $12.0M | $8.1M | $9.1M | $9.4M | $7.1M | $2.7M |
| Operating expenses | $24.1M | $18.4M | $21.3M | $18.5M | $18.0M | $5.6M |
| Operating income | −$23.3M | −$16.5M | −$21.0M | −$18.0M | −$17.5M | −$3.8M |
| Operating margin | −1,942.20% | −690.72% | −2,966.01% | −1,919.47% | −2,465.54% | −6,869.09% |
| EBITDA | −$22.5M | −$15.8M | −$20.3M | −$17.3M | −$17.5M | −$3.8M |
| EBITDA margin | −1,875.48% | −661.45% | −2,867.28% | −1,845.00% | −2,465.54% | −6,869.09% |
| Net income | −$22.7M | −$16.0M | −$21.4M | −$18.8M | −$17.0M | −$3.7M |
| Net profit margin | −1,893.58% | −667.77% | −3,020.17% | −2,003.72% | −2,407.49% | −6,765.45% |
| Basic EPSper basic share | -$0.00 | -$0.00 | -$0.01 | -$0.90 | -$0.90 | -$0.23 |
| Diluted EPSper diluted share | -$0.00 | -$0.00 | -$0.01 | -$0.90 | -$0.90 | -$0.23 |
Owners
Reported shareholders
4.47%of listed shares
MILLENNIUM MANAGEMENT LLC1.35M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
MILLENNIUM MANAGEMENT LLC | 4.47%1.35M shares |
Logos Global Management LP | 4.25%1.29M shares |
Willard Stephen H | ≈2.61%789.73K shares |
Hare Joshua | ≈2.38%721.8K shares |
Lehr Paul T | ≈1.94%588.57K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 1.92%581.31K shares |
Locklear Lisa | ≈1.54%465.69K shares |
Agafonova Nataliya | ≈1.50%453.42K shares |
Blass Devin | ≈1.46%441.54K shares |
Hashad Mohamed Wa'el Ahmed | ≈1.39%420.9K shares |
Soffer Rock | ≈0.75%226.03K shares |
BlackRock, Inc. | 0.74%224.17K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.67%203.76K shares |
JANE STREET GROUP, LLC | 0.63%190.37K shares |
VANGUARD FIDUCIARY TRUST CO | 0.46%140.13K shares |
Mariner, LLC | 0.42%126K shares |
Powell James Nathaniel | ≈0.41%125.59K shares |
ADAR1 Capital Management, LLC | 0.36%108.41K shares |
Beacon Pointe Advisors, LLC | 0.33%100K shares |
Virtu Financial LLC | 0.19%58.58K shares |
Percentages use 30.27M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 11, 2025Form 4 | Locklear LisaChief Financial Officer | BuyClass A Common Stock | 11.8K | — | — | 251.0K |
| Aug 11, 2025Form 4 | Locklear LisaChief Financial Officer | BuyWarrant (right to buy) · derivative | 29.4K | — | — | 29.4K |
| Aug 11, 2025Form 4 | Baluch KhosoDirector | BuyClass A Common Stock | 11.8K | — | — | 52.5K |
| Aug 11, 2025Form 4 | Baluch KhosoDirector | BuyWarrant (right to buy) · derivative | 29.4K | — | — | 29.4K |
| May 30, 2025Form 4 | Soffer RockDirector | SellClass A Common Stock | 11.0K | $1.25 | $13.8K | 209.0K |
Community posts
Longeveron’s infant heart-disease trial misses its primary endpoint
Longeveron ($LGVN) said its ELPIS II Phase 2b study in infants with hypoplastic left heart syndrome failed to meet its primary endpoint. The 40-patient trial assessed right-ventricular function after 12 months. The reported treatment differ ...
